A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Exclusion Criteria

• •Cohort A:
• •* Breast cancer amenable to treatment with curative intent.
• •* Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications, such as lymphangitic lung metastases, radiographic evidence of intratumoral cavitation or invasion/infiltration of a major blood vessel, bone marrow replacement, carcinomatous meningitis, significant symptomatic liver metastases, symptomatic pericardial effusion, symptomatic peritoneal carcinomatosis, or the need to achieve rapid symptom control.
• •Cohort B:
• •* Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), borderline tumors (low malignant potential), mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor, low-grade serous, low-grade endometrioid, and undifferentiated carcinoma.
• •* Has platinum-resistant ovarian cancer (defined as disease that has progressed per radiographic imaging within 180 days after the last dose of first-line \[1L\] platinum-based therapy) or platinum-refractory ovarian cancer (defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of 1L platinum based therapy).
• •* Is a candidate for curative-intent surgery or curative-intent radiotherapy for ovarian cancer.
• •Cohort C:
• •* Is a candidate for curative-intent surgery or curative-intent radiotherapy.
• •All Cohorts:
• •* Has confirmed or suspected adrenal metastases.
• •* Has known difficulty in tolerating oral medications, unable to swallow orally administered medication, or conditions which would impair absorption of oral medications.
• •* Has any prior history or current condition of adrenal insufficiency.
• •* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• •* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
• •* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
• •* Has known active central nervous system metastases and/or carcinomatous meningitis.
• •* Has a history of stem cell/solid organ transplant.
• •* Has not adequately recovered from major surgery or has ongoing surgical complications.